AIM ImmunoTech Beheer

Beheer criteriumcontroles 3/4

De CEO AIM ImmunoTech is Thomas Equels, benoemd in Aug2015, heeft een ambtstermijn van 9.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.08M, bestaande uit 78.6% salaris en 21.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.36% van de aandelen van het bedrijf, ter waarde $ 373.26K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.7 jaar en 8.3 jaar.

Belangrijke informatie

Thomas Equels

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	78.6%
Dienstverband CEO	9.3yrs
Eigendom CEO	2.4%
Management gemiddelde ambtstermijn	8.7yrs
Gemiddelde ambtstermijn bestuur	8.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Thomas Equels's beloning veranderd ten opzichte van AIM ImmunoTech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$1m	US$850k	-US$29m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$1m	US$850k	-US$19m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$2m	US$850k	-US$19m
Sep 30 2021	n/a	n/a	-US$17m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$3m	US$807k	-US$14m
Sep 30 2020	n/a	n/a	-US$12m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$890k	US$703k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$10m
Dec 31 2018	US$1m	US$751k	-US$10m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$987k	US$713k	-US$8m

Compensatie versus markt: De totale vergoeding ($USD 1.08M ) Thomas } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.16K ).

Compensatie versus inkomsten: De vergoeding van Thomas is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Thomas Equels (71 yo)

9.3yrs

Tenure

US$1,081,301

Compensatie

Mr. Thomas K. Equels, Esq. M.S., J.D. serves as Director at BioFlorida Inc since August 2021. He serves as the Chief Executive Officer of AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.)...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Equels	Executive Vice Chairman	9.3yrs	US$1.08m	2.36% $ 373.3k
Robert Dickey	Chief Financial Officer	2.6yrs	US$64.48k	0% $ 0
Peter Rodino	COO, Executive Director of Governmental Relations	8.1yrs	US$527.64k	0.63% $ 100.3k
Christopher McAleer	Scientific Officer	1.9yrs	geen gegevens	geen gegevens
Ann Marie Coverly	Director of Administration & Human Resources and Deputy Investor Relations Coordinator	11.8yrs	geen gegevens	geen gegevens
Ralph Cavalli	Vice President of QC & Manufacturing	14.6yrs	geen gegevens	geen gegevens

8.7yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AIM is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Equels	Executive Vice Chairman	16yrs	US$1.08m	2.36% $ 373.3k
Ronald H. Brus	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
William Mitchell	Independent Chairman of the Board & Member of Scientific Advisory Board	26.3yrs	US$139.37k	0.12% $ 19.1k
Christopher Nicodemus	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Nancy Bryan	Independent Director	1.7yrs	US$93.75k	0.061% $ 9.6k
Stewart Appelrouth	Independent Director	8.3yrs	US$139.37k	0.38% $ 59.9k
W. Burnette	Chairman of Scientific Advisory Board	1.6yrs	geen gegevens	geen gegevens
Philip Roane	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

8.3yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AIM wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.3 jaar).

AIM ImmunoTech Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Executive Vice Chairman recently bought US$50k worth of stock

Recent updates

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

Price target increased by 19% to US$4.25

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Ted D. Kellner Sends a Notice to AIM ImmunoTech

Consensus EPS estimates fall by 15%

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Second quarter 2024 earnings released: US$0.035 loss per share (vs US$0.10 loss in 2Q 2023)

Todd Deutsch Sends Notice of Intent to Nominate Candidates to AIM ImmunoTech Board

AIM ImmunoTech Inc. Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of A Combination Therapy

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

Consensus revenue estimates increase by 52%

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.076 loss in 1Q 2023)

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

Price target decreased by 30% to US$2.75

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Consensus EPS estimates fall by 12%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen

AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation

Consensus revenue estimates increase by 15%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Price target decreased by 7.8% to US$4.92

Price target decreased by 7.7% to US$5.00

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022)

Consensus revenue estimates decrease by 83%, EPS upgraded

AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod)

Executive Vice Chairman recently bought US$50k worth of stock

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Consensus revenue estimates fall by 34%

Insufficient new directors

AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen

ASFV Committee Issues a Statement on Ruling in Delaware Action

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech

AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions

Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma

Consensus revenue estimates fall by 23%

AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer

Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data

Consensus forecasts updated

AIM ImmunoTech Inc. Provides Update on Ampligen Long COVID Development Program

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind